MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Abstract

Aim: Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients; however, breast cancers have exhibited minimal response to single agent ICI therapy. There is a significant need to identify novel targets capable of increasing cancer cell immunogenicity and response to ICIs in breast cancer. Mitogen activated protein kinase (MAPK) signaling is essential for many cellular processes but the relationship between MAPK signaling and cancer cell immunogenicity is less well understood. Recent reports suggest that MEK inhibition (MEKi) affects the tumor-immune microenvironment by altering the expression of interferon responsive PD-L1 and MHC-I through unknown mechanisms.

Methods: Using western blotting and flow cytometry, we sought to determine whether MEKi affects JAK-STAT signaling upstream of PD-L1 and MHC-I expression in a panel of mouse mammary cancer and triple negative breast cancer cell lines.

Results: The cell lines tested exhibited increased STAT activation in response to MEKi treatment. Furthermore, MEKi-induced MHC-I and PD-L1 expression are dependent upon STAT1 in MMTV-Neu cells. Interestingly, MEKi-induced STAT activation and interferon-responsive protein expression are abrogated with ErbB-family inhibitor co-treatment in MMTV-Neu cells, suggesting ErbB receptor signaling dependence, but not in basal-like cell lines. Importantly, analysis of basal-like breast cancer patient samples exhibited an inverse relationship between STAT1 and Ras/MAPK activation signatures.

Conclusion: These findings suggest that MAPK signaling and STAT activation are inversely related in both mouse and human mammary tumors. This work also supports further study of MEKi to increase STAT signaling and potentially, immunotherapy responses through increased MHC-I and PD-L1 expression.

Keywords

Mitogen activated protein kinase signaling / immunogenicity / MHC-I / PD-L1

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018..CA Cancer J Clin2018;68:7-30

[2] Kim C,Sei E,Hartman J.Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing..Cell2018;173:879-93.e13 PMCID:PMC6132060

[3] Adams S,Demaria S,Perez EA.Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199..J Clin Oncol2014;32:2959-66 PMCID:PMC4162494

[4] Loi S,Salgado R,Jose V.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial..Ann Oncol2014;25:1544-50

[5] Vikas P,Zhang W.The clinical promise of immunotherapy in triple-negative breast cancer..Cancer Manag Res2018;10:6823-33 PMCID:PMC6292225

[6] Schmid P,Rugo HS,Barrios CH.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer..N Engl J Med2018;379:2108-21

[7] Loi S,Beavis PA,Denkert C.RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors..Clin Cancer Res2016;22:1499-509 PMCID:PMC4794351

[8] Balko JM,Coakley VL.MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC..Cancer Biol Ther2009;8:522-30

[9] TCGAComprehensive molecular portraits of human breast tumours..Nature2012;490:61-70 PMCID:PMC3465532

[10] Cerami E,Dogrusoz U,Sumer SO.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data..Cancer Discov2012;2:401-4 PMCID:PMC3956037

[11] Haibe-Kains B. In: genefu R package: Relevant Functions for Gene Expression Analysis, Especially in Breast Cancer. 2009. Available from: http://www.bioconductor.org/packages/release/bioc/html/genefu.html. [Last accessed on 13 Apr 2020]

[12] Team RC.R: A language and environment for statistical computing. In: Vienna, Austria: R foundation for statistical computing;2015;

[13] Balko JM,Wang K,Young CD.Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets..Cancer Discov2014;4:232-45 PMCID:PMC3946308

[14] Khodarev NN,Labay E,Roizman B.STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells..Proc Natl Acad Sci U S A2004;101:1714-9 PMCID:PMC341831

[15] Weichselbaum RR,Yoon T,Baker SW.An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer..Proc Natl Acad Sci U S A2008;105:18490-5 PMCID:PMC2587578

[16] Song TL,Laurensia Y,Tan J.Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma..Blood2018;132:1146-58 PMCID:PMC6148343

[17] Mazurkiewicz-Munoz AM,Kouadio JL,Jensen ON.Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor..Mol Cell Biol2006;26:4052-62 PMCID:PMC1489095

[18] Rawlings JS,Harrison DA.The JAK/STAT signaling pathway..J Cell Sci2004;117:1281-3

[19] Jain N,Fong SL,Cao X.Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)..Oncogene1998;17:3157-67

[20] Diebold SS,Koch N.MHC class II presentation of endogenously expressed antigens by transfected dendritic cells..Gene Therapy2001;8:487-93

[21] Ahn J,Rabasa Capote A,Barber GN.Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells..Cancer Cell2018;33:862-73.e5 PMCID:PMC6177226

[22] Chung J,Grammer TC.STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation..Mol Cell Biol1997;17:6508-16 PMCID:PMC232504

[23] Campbell MJ,Lobo M.Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse..In Vitro Cell Dev Biol Anim2002;38:326-33

[24] Nagathihalli NS,Lamichhane P,Shi C.Inverse Correlation of STAT3 and MEK signaling mediates resistance to RAS pathway inhibition in pancreatic cancer..Cancer Res2018;78:6235-46 PMCID:PMC6878978

[25] Pratilas CA,Ye Q,Sander C.(V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway..Proc Natl Acad Sci U S A2009;106:4519-24 PMCID:PMC2649208

[26] Dushyanthen S,Caramia F,Mintoff CP.Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer..Nat Commun2017;8:606 PMCID:PMC5605577

[27] Razavi P,Xu G,Ross DS.The genomic landscape of endocrine-resistant advanced breast cancers..Cancer Cell2018;34:427-38.e6 PMCID:PMC6327853